Stocks

Dexco (Diabete MedTech company) is delivering on its promises

Dexcom broke $1B in revenue in 2018, plans to outsource some customer support (mobi health news)

  • Continuous glucose monitoring (CGM) giant Dexcom recently reported Q4 2018 earnings, stating it broke USD1bn in annual revenue in 2018 while increasing adoption rates, and announcing outsourcing plans.
  • Q418 revenue of $338m was in line with the Jan. 7th preliminary announcement (“sales to exceed $331m,” BCM est. $288m).
  • Management reiterated sales guidance of 15-20% growth ($1.19-$1.24bn), and set a GM target of 65% with Adj. Op margin of 5.5%, and Adj. EBITDA of 18%.

Analysis and Comments

  • A newly announced restructuring initiative is incremental to forecasts and represents upside to future margin expansion prospects. This should help Dexcom drive leverage as it strives for the 2023 15% operating margin target set at the Dec. 2018 analyst day.
  • This is one of the leading companies in sectors linked to the diabetes value chain that are likely to benefit.

Related posts

Quovo Inevitable Will Get Hurt By Huawei Ban

rollandthomas

Nifty 50 Is Going Down To 10,000

rollandthomas

Will $TSLA succeed? Can Elon turn it around? Buy, Sell, or Run

heyimsnuffles
No comments yet